EQL has entered into an exclusive distribution agreement with Pharmalink for its product Mellozzan (melatonin) for the GCC (Gulf Cooperation Council) region comprising of United Arab Emirates, Saud...
EQL will shortly conclude the 5-year plan for 2020/21 – 2024/25. Thus, the Company today 7 March presents new financial targets for the period 2024/25 – 2028/29.
According to the resolution of the 2024 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest ...
Sales and operating profit growth, significant product acquisition signed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUI...
